anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Epithelioid angiomyolipoma (EAML) is a rare variant of angiomyolipoma that predominantly consists of epithelioid cells and belongs to the perivascular epithelioid cell neoplasm (PEComa) family. The majority of EAMLs arise in the kidneys, and primary hepatic EAML appears to be much less common than renal EAML. Most PEComas arise sporadically, but may be associated with tuberous sclerosis complex (TSC), an autosomal dominant genetic disorder characterized by germline mutations in the TSC1 or TSC2 genes. However, PEComas have previously been reported in five patients with Li-Fraumeni syndrome (LFS), which is an inherited cancer susceptibility disorder resulting from germline mutations in the TP53 tumor suppressor gene.
CASE PRESENTATION: We report a 49-year-old female patient with hepatic EAML and pancreatic cancer. Because she had previously been diagnosed with bilateral breast cancer at the age of 30, we performed a comprehensive genetic analysis to identify genetic alterations associated with any cancer predisposition syndrome. Whole-exome sequencing of a blood sample identified a heterozygous germline variant of TP53 (NM_000546.5):c.708C>A, and targeted next-generation sequencing of liver EAML and pancreatic cancer tissue samples demonstrated the same TP53 (NM_000546.5):c.708C>A variant in both. This, plus the patient's history of early-onset breast cancer, met the 2015 version of the Chompret criteria for diagnosis of LFS.
CONCLUSIONS: There have been very few case reports regarding the presence of PEComa in LFS, and to the best of our knowledge, this is the first report of EAML of the liver in a patient with LFS.
Barbiturates may be habit forming. Tolerance and psychological and physical dependence may occur with continued use (see DRUG ABUSE AND DEPENDENCE). Barbiturates should be administered with caution, if at all, to patients who are mentally depressed, have suicidal tendencies, or have a history of drug abuse.

Elderly or debilitated patients may react to barbiturates with marked excitement, depression, or confusion. In some persons, especially children, barbiturates repeatedly produce excitement rather than depression. In patients with hepatic damage, barbiturates should be administered with caution and initially in reduced doses. Barbiturates should not be administered to patients showing the premonitory signs of hepatic coma.

The systemic effects of exogenous and endogenous corticosteroids may be diminished by phenobarbital. Thus, this product should be administered with caution to patients with borderline hypoadrenal function, regardless of whether it is of pituitary or of primary adrenal origin.
PURPOSE:To efficiently produce an emulsion in a system low in the concn. of a surfactant by preliminarily treating the surface of a microporous membrane in order to adsorb a nonionic surfactant on the membrane. CONSTITUTION:A liquid being a dispersing phase is introduced into a liquid being a continuous phase under pressure through a microporous membrane having uniform pores to produce an emulsion. At this time, surface treatment for adsorbing a nonionic surfactant such as a sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester on the microporous membrane is performed by infiltrating the surfactant into the membrane or circulating the same to the membrane in a concn. of 1.0-0.1wt.% for about 5-10hr or in a concn. of about 2-20wt.% for about 0.5-1hr.
The leds will initially be measured in the photobiophysics laboratory of the University of São Paulo - Ribeirão Preto, regarding wavelength parameters, beam divergence, nominal power and fluency. The application will be in the graft donor area (scalp) of burn patients. The applied fluence will be 4J / cm2.
Because captopril tablets are excreted primarily by the kidneys, excretion rates are reduced in patients with impaired renal function. These patients will take longer to reach steady-state captopril levels and will reach higher steady-state levels for a given daily dose than patients with normal renal function. Therefore, these patients may respond to smaller or less frequent doses.

Accordingly, for patients with significant renal impairment, initial daily dosage of captopril tablets should be reduced, and smaller increments utilized for titration, which should be quite slow (one- to two-week intervals). After the desired therapeutic effect has been achieved, the dose should be slowly back-titrated to determine the minimal effective dose. When concomitant diuretic therapy is required, a loop diuretic (e.g., furosemide), rather than a thiazide diuretic, is preferred in patients with severe renal impairment (see WARNINGS: Anaphylactoid Reactions During Membrane Exposure and PRECAUTIONS: Hemodialysis).
Epidemiological evidence presents that dust storms are related to respiratory diseases, such as pulmonary fibrosis (PF). However, the precise underlying mechanisms of SPM-elicited adverse effects still need to be investigated. Epithelial-mesenchymal transition (EMT) process is a characteristic of PF. We discussed whether suspended particulate matter (SPM) is involved in EMT induction via transforming growth factor-β1 (TGF-β1). In this study, a detailed elemental analysis (55 elements), particle size, and morphology were determined. To investigate the toxicity of SPM, an MTT test was performed to detect cell viability. Next, A549 cells were exposed to selected concentrations of SPM (20 and 40 µg/mL) for single and repeated exposures. The DCFH-DA assay showed that exposure to SPM could produce reactive oxygen species (ROS). The ELISA assay demonstrated increased levels of interleukin-8 (IL-8) and TGF-β1 in the supernatant. Western blot was used to detect the expression of proteins associated with EMT and the SMAD3-dependent pathway. Results of western blot demonstrated that E-cadherin was reduced, whereas p-SMAD3, vimentin, and α-smooth muscle actin were elevated. Our findings indicated that SPM triggered EMT by induction of oxidative stress, inflammation, and the TGF-β1/SMAD3 pathway activation.
The invention belongs to the technical field of medicines and especially relates to a sprida free-dried powder injection and its preparation method. In recent years, pharmacological researches continuously show that sprida has an effect of inhibiting the growth of a plurality of mice transplanted tumor of S180, U14, H22 and the like. In addition, oxysophoridine has obvious internal inhibition system, has an obvious effect of inhibiting appearance, behavior and automatic action of mice, can be resistant to inflammation and virus, can improve heart functions and reduce heart rate of mice. However, as it is easy to absorb moisture and is easy to deteriorate during the production and storage processes of tablet and water injection, it is hard to guarantee drug safety. Considering from the angle of clinical treatment, the injection can avoid first pass effect of liver as well as damage of gastrointestinal tract and has advantages of fast onset, high bioavailability, small medication dosage and the like. Therefore, the freeze-dried powder injection containing a proper amount of an excipient with sprida being a main component is prepared so as to solve a big problem of sprida for medicinal purposes.
Subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours. At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals). Lastly, they will be asked to fill out a satisfaction survey.
Study participants are randomly assigned to one of two treatment groups. Participants received leuprolide or goserelin for 6 months. In period 1 participants received thalidomide orally 200 mg a day. Patients will be followed until PSA progression defined as prostate-specific antigen (PSA) level that returns to what it was before beginning leuprolide or goserelin or to 5 nanograms per liter, whichever is lower. The participants are returned to the leuprolide or goserelin treatment for 6 months. In period 2 participants received the placebo for thalidomide once a day.
Combined antiretroviral therapy (cART) has been associated with increased body weight accompanied by metabolic alterations in people living with human immunodeficiency virus (PLWH). To gain insight into the combined effects of cART components on adipocyte dysfunction, we assessed whether and how treatment of human adipocytes with dolutegravir (DTG) and the nucleotide-analog reverse-transcriptase inhibitors (NRTIs), tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF), alone and in combination, altered biological processes related to adipose tissue dysfunction. DTG, TAF, and TDF were applied to human Simpson-Golabi-Behmel syndrome (SGBS) adipose cells during differentiation (day 10) and ensuing differentiation (day 14). Expression of selected marker genes was determined by qPCR, the release of adipokines and inflammatory cytokines to the culture media was assessed, and cell respiration was measured. Adipogenesis was not altered by the combined treatment of human adipocytes. However, DTG at the highest dose repressed adipogenesis marker genes expression, and TAF and TDF appeared to mitigate this effect. DTG repressed the expression of adiponectin and the release of adiponectin and leptin in differentiating adipocytes, and these effects were mantained in combination with TAF and TDF. DTG plus TAF or TDF on human adipocytes enhanced inflammation and stress and increased the release of proinflammatory cytokines to the culture media. Together, our results show that combined therapy with these drugs can alter inflammation, cellular stress, and fibrosis in human adipocytes. These findings may improve our understanding and management of the effects of cART on body adiposity and metabolic dysregulation in PLWH.
A benzoquinone or hydroquinone for use in the topical treatment of bacterial infections. Preferred bacterial infections include staphylococcal and/or propionibacterial infections, particularly acne or MRSA. The benzoquinone or hydroquinone may be applied to the skin or nares, or non-living surfaces. The benzoquinone or hydroquinone may be halogenated, alkylated and/or methoxylated. The benzoquinones/hydroquinones include resorcinols and catechols. The preferred benzoquinone/hydroquinone is t-butylhydroquinone (TBHQ). Medicaments comprising a benzoquinone or hydroquinone may contain other drugs. The benzoquinone or hydroquinone may be formulated into cosmetics, skin or hair care preparations, pharmaceutical or veterinary preparations, toiletry products, laundry and/or fabric treatment products, agricultural products or horticultural products.
This study includes having an initial assessment completed; participating in a 6 session individual therapy intervention over a 7 week time period; and returning at 2 months after the individual therapy intervention for the "booster" follow-up session. During the individual intervention sessions, the youth and the parents will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15 to 20 minutes.
The present invention provides a thermoresponsive nanoparticle useful for the stabilization of enzymes in environments having a temperature greater than thirty degrees Centigrade. The thermoresponsive nanoparticle has (a) a functionalized enzyme conjugate having one or more enzymes or biological catalysts, the enzymes or biological catalysts are modified with palmitic acid N-hydroxysuccinimide ester and acryclic acid N-hydroxysuccinimide ester, and (b) a thermally responsive polymer, wherein the functionalized enzyme conjugate is encapsulated within the thermally responsive polymer. A nanocatalyst is provided that has one or more proteins. The proteins are covalently immobilized and encapsulated within a thermally responsive polymer shell. The proteins are one or more enzymes or biological catalysts. A method for protecting the proteins is also set forth.
PURPOSE: A composition containing Crataegis fructus extract for preventing hair loss or promoting hair growth is provided to promote growth of human keratinocytes and dermal papilla cells. CONSTITUTION: A composition for preventing hair loss or promoting hair growth contains Crataegis fructus extract as an active ingredient. The Crataegis fructus extract is isolated using water, alcohol of C1-C4, n-hexane, ethyl acetate, or their mixture. The extraction solvent is water, 70-95 weight% of ethanol solution, or methanol. The hair loss is Alopecia Areata, Androgenetic Alopecia, Alopecia syphlltiac, Alopecia seborrhecia, and Telogen Effluvium. The composition is formulated in powder, granule, tablet, capsule, suspension, emulsion, syrup, oral aerosol, external formulation or sterilization injection solution.
The endovenous treatment of the insufficient saphenous vein (large saphenous vein and small saphenous vein) is a standard procedure for years. There are different methods that cause an obliteration of the vein using heat. The adventage of these methods are low rates of minor and major complications compared to classic open surgery. There are also advantages concerning cosmetic and recurrence of varicous veins. Actually there are two different methods for the endovenous obliteration of the saphenous vein - lasers with wavelength of 1470nm or 1320nm and the radiofrequency method. The objective of this study is to compare these two different methods concerning postoperative pain, obliteration rate and the rate of pleased patients in 140 patients. All patients get an venous ultrasound investigation to determine the stadium of venous insufficiency. There are consecutive ultrasound investigations 10 days, 3 months and 12 months after surgical treatment.

In this study there are no additional risk factors for the included study patients except the risk of surgery.
Participants will view control messages approximately matched to the intervention messages on length, but discussing a neutral topic unrelated to sugary drinks (safe driving). Participants will view a total of 4 messages developed for this arm.
<P>PROBLEM TO BE SOLVED: To provide a therapeutic tool for athlete's foot widely or sufficiently sterilizing/exterminating bacteria of athlete's foot by deeply penetrating from corneal layer of epidermis to dermis through cuticle to eradicate the athlete's foot and inhibit recurrence of the disease.  <P>SOLUTION: The therapeutic agent for athlete's foot 4 comprises an extract obtained by blewing the bark of Hibiscus syriacus in hot water, and an alcohol which is easy to permeate from the skin. An inner sock 9 to which the therapeutic agent 4 permeates easily and widely and entirely penetrates by a capillary phenomenon, is put on the foot. A bag 8 with chemical liquid impermeability is applied on the outside of the inner sock 9, and the therapeutic liquid 4 is filled in the bag and the mouth of the bag 8 is tightly closed by a rubber band 6, the therapeutic liquid for athlete's foot 4 is not permeated, vaporized and leaked. An outer sock 7 is applied on the outside of the bag 8, the bag 8 with chemical liquid impermeability is constricted from outside and the therapeutic agent liquid 4 is raised up to a therapeutic agent liquid 4 raising level 2.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Doxorubicin (DOX) is a popular and potent anticancer drug, but its cardiotoxicity limits its clinical application. Shikonin has a wide range of biological functions, including antioxidant and anti-inflammatory effects. The aim of this study was to investigate the effects of shikonin on DOX-induced cardiac injury and to identify the underlying mechanisms. Mice receiving shikonin showed reduced cardiac injury response and enhanced cardiac function after DOX administration. Shikonin significantly attenuated DOX-induced oxidative damage, inflammation accumulation and cardiomyocyte apoptosis. Shikonin protects against DOX-induced cardiac injury by inhibiting Mammalian sterile 20-like kinase 1 (Mst1) and oxidative stress and activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. In conclusion, shikonin alleviates DOX-induced cardiotoxicity by inhibiting Mst1 and activating Nrf2. Shikonin may be used to treat DOX-induced cardiac injury.
Participants will receive no intervention, only to serve as a control site. Rates will be observed at 0, 6, and 12 months.
MITO-16 - MANGO-OV2 is a single-arm, open-label, non-comparative, multicenter, phase IV study. Patients will receive a combination of bevacizumab, paclitaxel and carboplatin as first line treatment (in-label dose and scheduling). This is an exploratory study attempting to identify potential prognostic clinical factors(such as hypertension) and prognostic biologic factors. Overall, 2 types of biomarkers are considered. Dynamic biomarkers are those expressing the changing nature of the disease in relation to the treatment or simply the tumour progression, these are typically not inherited. Genetic biomarkers are typically inherited and are expression of some characteristics potentially able to interfere with the treatment effect (i.e. Pharmacogenomics).

The safety of this regimen in routine clinical practice will also be described.
BACKGROUND: Although numerous studies have shown that bariatric surgery results in sustained weight loss and modifications in gut microbiota composition and cognitive function, the exact underlying mechanisms are unclear. This study aimed to investigate the effects of bariatric surgery on cognitive function through the microbiota-gut-brain axis (MGBA).
METHODS: Demographic data, serum samples, fecal samples, cognitive assessment scales, and resting-state functional connectivity magnetic resonance imaging (rs-fMRI) scans were obtained from 39 obese patients before and after (6 months) laparoscopic sleeve gastrectomy (LSG). PCA analysis, OPLS-DA analysis, and permutation tests were used to conduct fecal 16 S microbiota profiling, serum metabolomics, and neuroimaging analyses, and a bariatric surgery-specific rs-fMRI brain functional connectivity network was constructed. Spearman correlation analysis and Co-inertia analysis were employed to correlate significant alterations in cognitive assessment scales and resting-state functional connectivity difference networks with differential serum metabolites and 16 S microbiota data to identify key gut microbiota and serum metabolic factors.
RESULTS: LSG significantly reduced the weight of obese patients, with reductions of up to 28%. Furthermore, cognitive assessment scale measurements revealed that LSG enhanced cognitive functions, including memory (HVLT, p = 0.000) and executive function (SCWT, p = 0.008). Also, LSG significantly altered gut microbiota composition (p = 0.001), with increased microbial abundance and diversity (p < 0.05). Moreover, serum metabolite levels were significantly altered, revealing intergroup differences in 229 metabolites mapped to 72 metabolic pathways (p < 0.05, VIP > 1). Spearman correlation analysis among cognitive assessment scales, gut microbiota species, and serum metabolites revealed correlations with 68 gut microbiota species and 138 serum metabolites (p < 0.05). Furthermore, pairwise correlations were detected between gut microbiota and serum metabolites (p < 0.05). Functional neuroimaging analysis revealed that LSG increased functional connectivity in cognitive-related frontotemporal networks (FPN, p < 0.01). Additionally, normalization of the default mode network (DMN) and salience network (SN) connectivity was observed after LSG (p < 0.001). Further canonical correlation and correlation analysis suggested that the cognitive-related brain network changes induced by LSG were associated with key gut microbiota species (Akkermansia, Blautia, Collinsella, Phascolarctobacterium, and Ruminococcus, p < 0.05) and neuroactive metabolites (Glycine, L-Serine, DL-Dopa, SM (d18:1/24:1(15Z), p < 0.05).
CONCLUSION: These findings indicate the pathophysiological role of the microbiota-gut-brain axis in enhancing cognitive function after bariatric surgery, and the study provides a basis for clinical dietary adjustments, probiotic supplementation, and guidance for bariatric surgery, but further research is still needed.
TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100049403. Registered 02 August 2021, https://www.chictr.org.cn/ .
The present invention discloses a TIM-3 inhibitor which is a monoclonal antibody directed against TIM-3, wherein the variable domain of the heavy chain comprises the sequence of CDR-H1 given in SEQ ID NO. 1, the sequence of CDR-H2 given in SEQ ID NO. 2 and the sequence of CDR-H3 given in SEQ ID NO. 3, and the variable domain of the light chain comprises the sequence of CDR-L1 given in SEQ ID NO. 4, the sequence of CDR-L2 given in SEQ ID NO. 5 and the sequence of CDR-L3 given in SEQ ID NO. 6. The invention also extends to therapeutic uses of the inhibitors, compositions and methods for detecting TIM-3.
Therapeutic compounds have the formula:(X)j-(core moiety),J being an integer from one to three, the core moiety having at least one, five- to seven-membered ring and X being a racemic mixture, R or S enantiomer, slovate, hydrate, or salt of:   <IMAGE>   *C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH2)n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R1 and R2 may be a hydrogen, a straight or branched chain alkane or alkene of up to twelve carbon atoms in length, or -(CH2)wR5, w being an integer from two to fourteen and R5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R5 being hydroxy, chloro, fluoro, bromo, or C1-6 alkoxy. Or jointly, R1 and R2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R3 is a hydrogen or C1-3. Or, therapeutic compounds may also have the formula:   <IMAGE>   R4 is a hydrogen, a straight or branched chain alkane or alkene of up to eight carbon atoms in length, -(CH2)wR5, w being an integer from two to fourteen and R5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R5 being hydroxy, chloro, fluoro, bromo, or C1-6 alkoxy, or a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. r and s are independently integers from one to four, the sum (r+s) not being greater than five. t is an integer from one to fourteen and one or more carbon atoms of (CH2)s or (CH2)t may be substituted by a keto or hydroxy group.
Schizophrenia spectrum disorders are a major public health burden due to functional and cognitive impairment, psychosis and other symptoms, and high comorbidity. Unfortunately, current therapies have limited effectiveness in treating some of the symptoms and most of the cognitive deficits. Alternative biological models of the disease are needed for developing new and more effective treatment. Neuroinflammation has increasingly been implicated in the pathophysiology of schizophrenia. Patients with schizophrenia have signs of low-grade, chronic inflammation, including elevated blood levels of pro-inflammatory cytokines and other immune markers. Administration of LPS is the standard immune challenge to investigate the body's immune response in a wide range of disorders. Our goal is to use LPS to investigate whether schizophrenia patients have abnormal immune response to LPS and whether the abnormality is associated with specific brain imaging biomarkers.